FMP
Liminal BioSciences Inc.
LMNL
NASDAQ
Inactive Equity
Liminal BioSciences Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel small molecule drug therapeutics for inflammatory, fibrotic, and metabolic diseases in Canada and the United Kingdom. The company's lead product candidate is fezagepras (PBI-4050), which has been completed Phase I clinical trial for the treatment of idiopathic pulmonary, liver, cardiac, or skin fibrosis with fezagepras or related derivatives and respiratory diseases. It is also developing antagonist candidate programs, including G-protein coupled receptor 84 and Oxo-eicosanoid receptor 1, which are in preclinical stage. The company was formerly known as Prometic Life Sciences Inc. and changed its name to Liminal BioSciences Inc. in October 2019. Liminal BioSciences Inc. was incorporated in 1994 and is headquartered in Laval, Canada.
8.5 USD
0.01 (0.118%)
Historical Prices
From:
To:
We are unable to load the chart at this time.
About
ceo
Mr. Bruce Pritchard BA, CA, FIOD
sector
Healthcare
industry
Biotechnology
exchange
NASDAQ
Description
Liminal BioSciences Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel small molecule drug therapeutics for inflammatory, fibrotic, and metabolic diseases in Canada and the United Kingdom. The company's lead product candidate is fezagepras (PBI-4050), which has been completed Phase I clinical trial for the treatment of idiopathic pulmonary, liver, cardiac, or skin fibrosis with fezagepras or related derivatives and respiratory diseases. It is also developing antagonist candidate programs, including G-protein coupled receptor 84 and Oxo-eicosanoid receptor 1, which are in preclinical stage. The company was formerly known as Prometic Life Sciences Inc. and ch...
CIK
0001351172
ISIN
CA53272L1031
CUSIP
53272L103
Address
440 Armand-Frappier Boulevard
Phone
14507810115
Country
CA
Employee
251
IPO Date
Dec 18, 2009
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
LMNL Financial Summary
CIK
0001351172
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
53272L103
ISIN
CA53272L1031
Country
CA
Price
8.5
Beta
29.34
Volume Avg.
23.73k
Market Cap
27.62M
Shares
-
52-Week
3.1-8.5
DCF
2.85
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-1.24
P/B
-
Website
https://www.liminalbiosciences.com
Upgrades and Downgrades
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest LMNL News
It looks like there's no news available.
